CONTEXT: Pain and depression are two of the most prevalent and treatable cancer-related symptoms, each present in at least 20%-30% of oncology patients. OBJECTIVE: To determine the associations of pain and depression with health-related quality of life (HRQL), disability, and health care use in cancer patients. METHODS: The Indiana Cancer Pain and Depression study is a randomized clinical trial comparing telecare management vs. usual care for patients with cancer-related pain and/or clinically significant depression. In this article, baseline data on patients enrolled from 16 urban or rural community-based oncology practices are analyzed to test the associations of pain and depression with HRQL, disability, and health care use. RESULTS: Of the 405 participants, 32% had depression only, 24% pain only, and 44% both depression and pain. The average Hopkins Symptom Checklist 20-item depression score in the 309 depressed participants was 1.64 (on 0-4 scale), and the average Brief Pain Inventory (BPI) severity score in the 274 participants with pain was 5.2 (on 0-10 scale), representing at least moderate levels of symptom severity. Symptom-specific disability was high, with participants reporting an average of 16.8 of the past 28 days (i.e., 60% of their days in the past four weeks) in which they were either confined to bed (5.6 days) or had to reduce their usual activities by 50% (11.2 days) because of pain or depression. Moreover, 176 (43%) participants reported being unable to work because of health-related reasons. Depression and pain had both individual and additive adverse associations with quality of life. Most patients were currently not receiving care from a mental health or pain specialist. CONCLUSION:Depression and pain are prevalent and disabling across a wide range of types and phases of cancer, commonly co-occur, and have additive adverse effects. Enhanced detection and management of this disabling symptom dyad is warranted. Published by Elsevier Inc.
RCT Entities:
CONTEXT: Pain and depression are two of the most prevalent and treatable cancer-related symptoms, each present in at least 20%-30% of oncology patients. OBJECTIVE: To determine the associations of pain and depression with health-related quality of life (HRQL), disability, and health care use in cancerpatients. METHODS: The Indiana Cancer Pain and Depression study is a randomized clinical trial comparing telecare management vs. usual care for patients with cancer-related pain and/or clinically significant depression. In this article, baseline data on patients enrolled from 16 urban or rural community-based oncology practices are analyzed to test the associations of pain and depression with HRQL, disability, and health care use. RESULTS: Of the 405 participants, 32% had depression only, 24% pain only, and 44% both depression and pain. The average Hopkins Symptom Checklist 20-item depression score in the 309 depressed participants was 1.64 (on 0-4 scale), and the average Brief Pain Inventory (BPI) severity score in the 274 participants with pain was 5.2 (on 0-10 scale), representing at least moderate levels of symptom severity. Symptom-specific disability was high, with participants reporting an average of 16.8 of the past 28 days (i.e., 60% of their days in the past four weeks) in which they were either confined to bed (5.6 days) or had to reduce their usual activities by 50% (11.2 days) because of pain or depression. Moreover, 176 (43%) participants reported being unable to work because of health-related reasons. Depression and pain had both individual and additive adverse associations with quality of life. Most patients were currently not receiving care from a mental health or pain specialist. CONCLUSION:Depression and pain are prevalent and disabling across a wide range of types and phases of cancer, commonly co-occur, and have additive adverse effects. Enhanced detection and management of this disabling symptom dyad is warranted. Published by Elsevier Inc.
Authors: S L Du Pen; A R Du Pen; N Polissar; J Hansberry; B M Kraybill; M Stillman; J Panke; R Everly; K Syrjala Journal: J Clin Oncol Date: 1999-01 Impact factor: 44.544
Authors: Sean O'Mahony; Joseph Goulet; Alice Kornblith; Geraldine Abbatiello; Bernadette Clarke; Sarah Kless-Siegel; William Breitbart; Richard Payne Journal: J Pain Symptom Manage Date: 2005-05 Impact factor: 3.612
Authors: John W Williams; Martha Gerrity; Tracey Holsinger; Steve Dobscha; Bradley Gaynes; Allen Dietrich Journal: Gen Hosp Psychiatry Date: 2007 Mar-Apr Impact factor: 3.238
Authors: C S Cleeland; R Gonin; A K Hatfield; J H Edmonson; R H Blum; J A Stewart; K J Pandya Journal: N Engl J Med Date: 1994-03-03 Impact factor: 91.245
Authors: Erin E Krebs; Karl A Lorenz; Matthew J Bair; Teresa M Damush; Jingwei Wu; Jason M Sutherland; Steven M Asch; Kurt Kroenke Journal: J Gen Intern Med Date: 2009-05-06 Impact factor: 5.128
Authors: Ilene H Zuckerman; Amy J Davidoff; Mujde Z Erten; Bruce Stuart; Thomas Shaffer; J Samantha Dougherty; Candice Yong Journal: Support Care Cancer Date: 2014-08 Impact factor: 3.603
Authors: Sarah L Hagerty; Jarrod M Ellingson; Timothy B Helmuth; L Cinnamon Bidwell; Kent E Hutchison; Angela D Bryan Journal: Perspect Psychol Sci Date: 2019-06-07
Authors: Jocelyn C Que; Teresa T Sy Ortin; Karen O Anderson; Consuelo B Gonzalez-Suarez; Thomas W Feeley; Cielito C Reyes-Gibby Journal: J Palliat Med Date: 2013-09-18 Impact factor: 2.947
Authors: Laura P Forsythe; Erin E Kent; Kathryn E Weaver; Natasha Buchanan; Nikki A Hawkins; Juan L Rodriguez; A Blythe Ryerson; Julia H Rowland Journal: J Clin Oncol Date: 2013-04-22 Impact factor: 44.544